Innovative Nanoplatforms for Enhanced Gene Delivery and Therapeutic Applications

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (20 February 2025) | Viewed by 1036

Special Issue Editor


E-Mail Website
Guest Editor
School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
Interests: biomacromolecules; cancer therapy; drug resistance; drug controlled release; bionanomaterials; artificial cell
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue delves into the cutting-edge advancements in nanotechnology, emphasizing the development and application of novel nanoplatforms for gene delivery and therapeutic interventions. As gene delivery systems evolve from traditional vectors to sophisticated nanostructures, these innovations promise enhanced delivery efficiency, targeted specificity, and improved safety profiles.

Key areas of focus include the design and synthesis of advanced nanomaterials such as lipid-based nanoparticles, polymeric nanocarriers, and hybrid nanocomposites. Mechanistic studies will shed light on cellular uptake, intracellular trafficking, and gene expression facilitated by these nanoplatforms. Therapeutic applications will cover the treatment of genetic disorders, cancers, and overcoming chemoresistance through targeted gene delivery. Moreover, evaluations of biocompatibility, toxicity, and therapeutic efficacy will ensure the safety and effectiveness of these nanoplatforms.

This Special Issue aims to provide a comprehensive overview of the current innovations and future trends in nanotechnology-based gene delivery and therapeutic applications, inviting contributions that push the boundaries of current research and offer new insights into this rapidly evolving field.

I look forward to receiving your contributions.

Prof. Dr. Hongjing Dou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology
  • gene delivery
  • genetic disorders
  • enhanced delivery
  • gene expression
  • targeted therapeutics
  • cancers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 17773 KiB  
Article
Novel Peptide-Modified Zeolitic Imidazolate Framework-8 Nanoparticles with pH-Sensitive Release of Doxorubicin for Targeted Treatment of Colorectal Cancer
by Liming Gong, Heming Zhao, Liqing Chen, Yanhong Liu, Hao Wu, Chao Liu, Jing Feng, Chenfei Liu, Congcong Xiao, Qiming Wang, Mingji Jin, Zhonggao Gao, Wei Huang and Youyan Guan
Pharmaceutics 2025, 17(2), 246; https://doi.org/10.3390/pharmaceutics17020246 - 13 Feb 2025
Viewed by 818
Abstract
Background: Colorectal cancer (CRC) is one of the common malignant tumors. Chemotherapeutic agents represented by doxorubicin (DOX) are common adjuvant therapies for patients with advanced CRC. However, DOX suffers from dose-dependent cardiotoxicity and myelosuppression due to a lack of targeting and specificity, [...] Read more.
Background: Colorectal cancer (CRC) is one of the common malignant tumors. Chemotherapeutic agents represented by doxorubicin (DOX) are common adjuvant therapies for patients with advanced CRC. However, DOX suffers from dose-dependent cardiotoxicity and myelosuppression due to a lack of targeting and specificity, which severely limits its clinical application. Methods: Herein, we constructed a zeolitic imidazolate framework-8 (ZIF-8) modified by a novel peptide (LT peptide) to deliver the chemotherapeutic drug doxorubicin (DOX) for the targeted treatment of CRC. Results: In this study, LT-PEG@DOX@ZIF-8 nanoparticles were prepared by a simple method with suitable particle size and zeta potential, which were also capable of pH-responsive drug release. In vitro assays exhibited that LT-PEG@DOX@ZIF-8 nanoparticles were effectively taken up by C26 cells, significantly inhibited cell proliferation, and induced apoptosis. Furthermore, in mice models with colorectal tumors, LT-PEG@DOX@ZIF-8 nanoparticles also displayed specific tumor aggregation and exerted anti-tumor effects to prolong the survival of the mice. Conclusions: In conclusion, LT-PEG@DOX@ZIF-8 provides a promising strategy for the delivery of DOX to effectively treat CRC. Full article
Show Figures

Figure 1

Back to TopTop